WO2024040216A3 - Anti-ccr8 antibodies and uses thereof - Google Patents

Anti-ccr8 antibodies and uses thereof Download PDF

Info

Publication number
WO2024040216A3
WO2024040216A3 PCT/US2023/072462 US2023072462W WO2024040216A3 WO 2024040216 A3 WO2024040216 A3 WO 2024040216A3 US 2023072462 W US2023072462 W US 2023072462W WO 2024040216 A3 WO2024040216 A3 WO 2024040216A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
ccr8
cancer
treatment
methods
Prior art date
Application number
PCT/US2023/072462
Other languages
French (fr)
Other versions
WO2024040216A2 (en
Inventor
David T. BROUSSEAU
Gail Walkinshaw
Claudia WITSCHI
Original Assignee
Fibrogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen, Inc. filed Critical Fibrogen, Inc.
Publication of WO2024040216A2 publication Critical patent/WO2024040216A2/en
Publication of WO2024040216A3 publication Critical patent/WO2024040216A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are isolated monoclonal antibody anti-CCR8 antibodies, antigen binding fragments thereof, mutants thereof, variants thereof and uses thereof for the treatment of diseases such as cancer. The mutant antibodies have a complementarity-determining region 3 modified to eliminate post-translational modification, and to improve stability and potency of the antibody. The variant antibodies have various levels of afucosylation. Also provided herein are methods of use of the anti-CCR8 antibodies, including methods of treatment of cancer. Also provided are polynucleotides encoding the heavy chain or the light chain or the antigen-binding portion thereof described herein, and vectors, especially expression vector, including the polynucleotides described herein.
PCT/US2023/072462 2022-08-19 2023-08-18 Anti-ccr8 antibodies and uses thereof WO2024040216A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263399483P 2022-08-19 2022-08-19
US63/399,483 2022-08-19

Publications (2)

Publication Number Publication Date
WO2024040216A2 WO2024040216A2 (en) 2024-02-22
WO2024040216A3 true WO2024040216A3 (en) 2024-04-11

Family

ID=88020873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/072462 WO2024040216A2 (en) 2022-08-19 2023-08-18 Anti-ccr8 antibodies and uses thereof

Country Status (1)

Country Link
WO (1) WO2024040216A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021142002A1 (en) * 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof
WO2021163064A2 (en) * 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021194942A1 (en) * 2020-03-23 2021-09-30 Bristol-Myers Squibb Company Anti-ccr8 antibodies for treating cancer
WO2022136647A1 (en) * 2020-12-24 2022-06-30 Oncurious Nv Human ccr8 binders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE69334255D1 (en) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker for cancer and biosynthetic binding protein for it
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
EP2246333B1 (en) 2003-05-22 2012-10-24 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
DK1678314T3 (en) 2003-10-22 2012-12-03 Keck Graduate Inst Method of Synthesizing Heteromultimeric Polypeptides in Yeast Using a Haploid Mating Strategy
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
CN118176210A (en) 2021-08-20 2024-06-11 高诚生物医药公司 Anti-CCR 8 antibodies and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021142002A1 (en) * 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof
WO2021163064A2 (en) * 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021194942A1 (en) * 2020-03-23 2021-09-30 Bristol-Myers Squibb Company Anti-ccr8 antibodies for treating cancer
WO2022136647A1 (en) * 2020-12-24 2022-06-30 Oncurious Nv Human ccr8 binders

Also Published As

Publication number Publication date
WO2024040216A2 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
PT699237E (en) ANTI-EGFR CHAIN FVS AND ANTI-EGFR ANTIBODIES
GEP20074222B (en) Antibodies to cd40
IL276695A (en) Antibodies, pharmaceutical compositions and uses thereof
RU2010132956A (en) ANGIOPOETIN-2-SPECIFIC BINDING AGENTS
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
NZ547157A (en) Interferon Alpha Antibodies and their uses
NZ529571A (en) Human antibodies that bind human IL-12 and methods for producing
CA2501984A1 (en) Erythropoietin receptor binding antibodies
HUP9802401A2 (en) Monoclonal antibodies specific for different epitopes of human gp39 and methods for their use in diagnosis and therapy
NZ611387A (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
RS52889B (en) Therapeutic human anti-il-1r1 monoclonal antibody
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
WO2005056600B1 (en) Monoclonal antibodies that bind or neutralize dengue virus
TW200500377A (en) Method of humanizing immune system molecules
DE69429095T2 (en) HUMANIZED ANTIBODIES
WO2004001381A3 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
RS51853B (en) Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours
JP2024024114A5 (en)
WO2021203030A3 (en) Methods of use of anti-trem2 antibodies
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2021254574A3 (en) Cd38 antibodies for the treatment of human diseases
WO2024040216A3 (en) Anti-ccr8 antibodies and uses thereof
WO2003059259A3 (en) Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
MX2023010567A (en) Non-activating antibody variants.
WO2021226321A3 (en) Anti-tumor associated antigen antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23769061

Country of ref document: EP

Kind code of ref document: A2